---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053195"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:07:04.396316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q1 net loss $26.4M; STK-001 data supports disease modification

## Summary
- Net loss $26.4M ($0.57/share) vs $22.5M ($0.53) YoY; cash $178.6M at March 31, plus $120.3M net from April follow-on offering.
- STK-001 data from 81 patients showed durable seizure reductions and cognitive/behavior improvements; plans to discuss registrational study with regulators, update H2 2024.
- Revenue from Acadia collaboration $4.2M (down from $5.2M); R&D expenses rose to $22.4M from $19.6M.
- Appointed Jason Hoitt as CCO and Tommy Leggett as CFO.
- Plans to initiate Phase 1 OSPREY trial for STK-002 in ADOA in 2024; FALCON natural history data presented at ARVO.

## SEC filing metadata
- accession: 0000950170-24-053195
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/0000950170-24-053195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/stok-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053195
- JSON: https://secwatch.observer/filing/0000950170-24-053195.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053195.txt

## Key facts
- Earnings Releases
  Stoke Therapeutics, Inc. reported the three months ended March 31, 2024 results: revenue $4.2 million, net income $26.4 million, EPS $0.57 per share.
  - Period: the three months ended March 31, 2024
  - Revenue: $4.2 million
  - Net income: $26.4 million
  - EPS: $0.57 per share
  - Result: reported results
  source text: Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended March 31, 2024 was $4.2 million, compared to $5.2 million, for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/0000950170-24-053195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.